Figure 6

The mechanism by which NSC23925 acts to prevent the emergence of MDR in osteosarcoma. The U-2OS cells selected with paclitaxel alone developed a MDR phenotype with resistance to Pgp substrates, as well as decreased drug intracellular accumulation and enhanced drug efflux. However, NSC23925 specifically prevented overexpression of Pgp during chemotherapeutic drug treatment that subsequently allowed for the retention of intercellular drug accumulation and decreased drug efflux. Consequently, NSC23925 enabled tumour cells to remain sensitive to chemotherapeutic drugs and prevented the emergence of MDR during chemotherapy treatment.